Emerging peptide therapeutics for inflammatory autoimmune diseases

Current Pharmaceutical Design

Volumn 16, Issue 9, 2010, Pages 1136-1142

  Briand, Jean Paul ^a   Muller, Sylviane ^a  

^a INSTITUT DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

Author keywords

Autoimmunes diseases; Clinical trials; Inflammation; Peptide therapeutics

Indexed keywords

ADALIMUMAB; ATX MS 1467; CD28 ANTIGEN; CD4 ANTIGEN; CD40 ANTIGEN; CD8 ANTIGEN; DEAPEP277; EDRATIDE; EOTAXIN; ETANERCEPT; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLATIRAMER; HEAT SHOCK PROTEIN 60[336-351]; HISTONE 4[16-39]; INFLIXIMAB; INSULIN B CHAIN[9-23]; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 6; IPP 201101; KEYHOLE LIMPET HEMOCYANIN HUMAN TUMOR NECROSIS FACTOR ALPHA HETEROCOMPLEX; LEPTIN; LUPUZOR; MYELIN OLIGODENDROCYTE GLYCOPROTEIN[35-55]; P21 WAF CIP1[141-160] CARRIER PEPTIDE FUSION PROTEIN; PEPTIDE DERIVATIVE; PROTEIN P140; PROTEIN P277; PROTEOLIPID PROTEIN[139-151]; UNCLASSIFIED DRUG; UNINDEXED DRUG; VRT 102;

ABSENCE OF SIDE EFFECTS; ALLERGIC ENCEPHALOMYELITIS; ANKYLOSING SPONDYLITIS; AUTOINFLAMMATORY DISEASE; BEHCET DISEASE; CHRONIC INFLAMMATION; CLINICAL TRIAL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENTERITIS; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INSULIN DEPENDENT DIABETES MELLITUS; LONG TERM CARE; LUPUS ERYTHEMATOSUS; LUPUS ERYTHEMATOSUS NEPHRITIS; MULTIPLE SCLEROSIS; NONHUMAN; PALLIATIVE THERAPY; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; UNSPECIFIED SIDE EFFECT; UVEITIS; UVEORETINITIS; VASCULITIS;

EID: 77950241221     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210790963805     Document Type: Review

References (97)

1. Voulgari PV. Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs 2008; 13: 175-196
2. Leech MD, Anderton SM. Antigen-based therapies targeting the expansion of regulatory T cells in autoimmune and allergic disease. Chem Immunol Allergy 2008; 94: 201-210
3. Monneaux F, Muller S. Molecular therapies for systemic lupus erythematosus: clinical trials and future prospects. Arthritis Res Ther 2009; 11: 234.
4. Szekanecz Z, Koch AE. Vascular involvement in rheumatic diseases: 'vascular rheumatology'. Arthritis Res Ther 2008; 10: 224.
5. Roman-Blas JA, Jimenez SA. Targeting NF-kappaB: a promising molecular therapy in inflammatory arthritis. Int Rev Immunol 2008; 27: 351-374
6. Waldburger JM, Firestein GS. Garden of therapeutic delights: new targets in rheumatic diseases. Arthritis Res Ther 2009; 11: 206.
7. Smolen J, Kay J, Doyle M, Landewé R, Matteson E, Wollenhaupt J, et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 2009; 374: 210-221
8. Wallace DJ, Stohl W, Furie RA, Lisse JR, McKay JD, Merrill JT, et al. A phase II, randomized, double-blind, placebo-controlled, doseranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum 2009; 61: 1168-1178
9. Dall'era M, Chakravarty E, Wallace D, Genovese M, Weisman M, Kavanaugh A, et al. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum 2007; 56: 4142-4150
10. Barber DF, Bartolome A, Hernandez C, Flores JM, Redondo C, Fernandez-Harias C, et al. PI3gamma inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus. Nat Med 2005; 11: 933-935
11. Anderton SM. Peptide-based immunotherapy of autoimmunity: a path of puzzles, paradoxes and possibilities. Immunology 2001; 104: 367-376
12. Larché M, Wraith DC. Peptide-based therapeutic vaccines for allergic and autoimmune diseases. Nat Med 2005; 11: S69-75.
13. Hauff K, Zamzow C, Law WJ, De Melo J, Kennedy K, Los M. Peptide-based approaches to treat asthma, arthritis, other autoimmune diseases and pathologies of the central nervous system. Arch Immunol Ther Exp 2005; 53: 308-320
14. Pinilla C, Appel JR, Campbell GD, Buencamino J, Benkirane N, Muller S, et al. Cross-reactive, all-D peptides recognized by an anti-carbohydrate antibody identified from a positional scanning library. J Mol Biol 1998; 283: 1013-1025
15. Hahn BH, Singh RR, Wong WK, Tsao BP, Bulpitt K, Ebling FM. Treatment with a consensus peptide based on amino acid sequences in autoantibodies prevents T cell activation by autoantigens and delays disease onset in murine lupus. Arthritis Rheum 2001; 44: 432-441
16. Singh RP, La Cava A, Wong M, Ebling F, Hahn BH. CD8+ T cellmediated suppression of autoimmunity in a murine lupus model of peptide-induced immune tolerance depends on Foxp3 expression. J Immunol 2007; 178: 7649-7657
17. + T cells in lupus-prone (NZBxNZW)F1 mice by differentially regulating Foxp3 and PD1 molecules. J Immunol 2008; 180: 2069-2080
18. Zouali M, Mageed RA. Cellular interactions and signaling defects in lupus. Lupus 2008; 17: 236-240
19. Zinger H, Eilat E, Meshorer A, Mozes E. Peptides based on the complementarity-determining regions of a pathogenic autoantibody mitigate lupus manifestations of (NZB x NZW)F1 mice via active suppression. Int Immunol 2003; 15: 205-214
20. Luger D, Dayan M, Zinger H, Liu JP, Mozes E. A peptide based on the complementarity determining region 1 of a human monoclonal autoantibody ameliorates spontaneous and induced lupus manifestations in correlation with cytokine immunomodulation. J Clin Immunol 2004; 24: 579-590
21. Sharabi A, Mozes E. The suppression of murine lupus by a tolerogenic peptide involves Foxp3-expressing CD8 cells that are required for the optimal induction and function of Foxp3-expressing CD4 cells. J Immunol 2008; 181: 3243-3251
22. Sela U, Sharabi A, Dayan M, Hershkoviz R, Mozes E. The role of dendritic cells in the mechanism of action of a peptide that ameliorates lupus in murine models. Immunology 2009; 128(1 Suppl): e395-405.
23. Kaliyaperumal A, Michaels MA, Datta SK. Antigen-specific therapy of murine lupus nephritis using nucleosomal peptides: tolerance spreading impairs pathogenic function of autoimmune T and B cells. J Immunol 1999; 162: 5775-5783
24. Wu HY, Ward FJ, Staines NA. Histone peptide-induced nasal tolerance: suppression of murine lupus. J Immunol 2002; 169: 1126-1134
25. Wu HY, Staines NA. A deficiency of CD4+CD25+ T cells permits the development of spontaneous lupus-like disease in mice, and can be reversed by induction of mucosal tolerance to histone peptide autoantigen. Lupus 2004; 13: 192-200.
26. Kang HK, Michaels MA, Berner BR, Datta SK. Very low-dose tolerance with nucleosomal peptides controls lupus and induces potent regulatory T cell subsets. J Immunol 2005; 174: 3247-3255
27. Suen JL, Chuang YH, Tsai BY, Yau PM, Chiang BL. Treatment of murine lupus using nucleosomal T cell epitopes identified by bone marrow-derived dendritic cells. Arthritis Rheum 2004; 50: 3250-3259
28. Mihaylova N, Voynova E, Tchorbanov A, Nikolova M, Michova A, Todorov T, et al. Selective silencing of disease-associated B-lymphocytes by chimeric molecules targeting their Fc gamma IIb receptor. Int Immunol. 2008; 20: 165-175
29. Lu L, Kaliyaperumal A, Boumpas DT, Datta SK. Major peptide autoepitopes for nucleosome-specific T cells of human lupus. J Clin Invest 1999; 104: 345-355
30. Kaliyaperumal A, Michaels MA, Datta SK. Naturally processed chromatin peptides reveal a major autoepitope that primes pathogenic T and B cells of lupus. J Immunol 2002; 168: 2530-2537
31. Kang HK, Lui M, Datta SK. Low-dose peptide tolerance therapy of lupus generates plasmacytoid dendritic cells that cause expansion of autoantigen-specific regulatory T cells and contraction of inflammatory Th17 cells. J Immunol 2007; 178: 7849-7858.
32. Amital H, Heilweil M, Ulmansky R, Szafer F, Bar-Tana R, Morel L, et al. Treatment with a laminin-derived peptide suppresses lupus nephritis. J Immunol 2005; 175: 5516-5523
33. Delaleu N, Madureira AC, Immervoll H, Jonsson R. Inhibition of experimental Sjögren's syndrome through immunization with HSP60 and its peptide amino acids 437-460. Arthritis Rheum 2008; 58: 2318-2328
34. Elias D, Reshef T, Birk OS, van der Zee R, Walker MD, Cohen IR. Vaccination against autoimmune mouse diabetes with a T-cell epitope of the human 65-kDa heat shock protein. Proc Natl Acad Sci USA 1991; 88: 3088-3091
35. Jin L, Zhu A, Wang Y, Chen Q, Xiong Q, Li J, et al. A Th1-recognized peptide P277, when tandemly repeated, enhances a Th2 immune response toward effective vaccines against autoimmune diabetes in nonobese diabetic mice. J Immunol 2008; 180: 58-63.
36. TM in C-peptide positive type 1 diabetes patients. Diabetes Metab Res Rev 2007; 23: 269-275
37. Huurman VA, van der Meide PE, Duinkerken G, Willemen S, Cohen IR, Elias D, et al. Immunological efficacy of heat shock protein 60 peptide DiaPep277 therapy in clinical type I diabetes. Clin Exp Immunol 2008; 152: 488-497
38. Stanford M, Whittall T, Bergmeier LA, Lindblad M, Lundin S, Shinnick T, et al. Oral tolerization with peptide 336-351 linked to cholera toxin B subunit in preventing relapses of uveitis in Behcet's disease. Clin Exp Immunol 2004; 137: 201-208
39. Daniel D, Wegmann DR. Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-(9-23). Proc Natl Acad Sci USA 1996; 93: 956-960
40. Hutchings P, Cooke A. Protection from insulin dependent diabetes mellitus afforded by insulin antigens in incomplete Freund's adjuvant depends on route of administration. J Autoimmun 1998; 11: 127-130
41. Alleva DG, Gaur A, Jin L, Wegmann D, Gottlieb PA, Pahuja A, et al. Immunological characterization and therapeutic activity of an altered-peptide ligand, NBI-6024, based on the immunodominant type 1 diabetes autoantigen insulin B-chain (9-23) peptide. Diabetes 2002; 51: 2126-2134
42. Kobayashi M, Abiru N, Arakawa T, Fukushima K, Zhou H, Kawasaki E, et al. Altered B: 9-23 insulin, when administered intranasally with cholera toxin adjuvant, suppresses the expression of insulin autoantibodies and prevents diabetes. J Immunol 2007; 179: 2082-2088
43. Tian J, Kaufman DL. Antigen-based therapy for the treatment of type I diabetes. Diabetes 2009; 58: 1939-1946
44. Sloan-Lancaster J, Allen PM. Altered peptide ligand-induced partial T cell activation: molecular mechanisms and role in T cell biology. Ann Rev Immunol 1996; 14: 1-27.
45. Leech MD, Chung CY, Culshaw A, Anderton SM. Peptide-based immunotherapy of experimental autoimmune encephalomyelitis without anaphylaxis. Eur J Immunol 2007; 37: 3576-3581
46. Jiang Z, Li H, Fitzgerald DC, Zhang GX, Rostami A. MOG(35-55) i.v. suppresses experimental autoimmune encephalomyelitis partially through modulation of Th17 and JAK/STAT pathways. Eur J Immunol 2009; 39: 789-799
47. Wegmann KW, Wagner CR, Whitham RH, Hinrichs DJ. Synthetic Peptide dendrimers block the development and expression of experimental allergic encephalomyelitis. J Immunol 2008; 181: 3301-3309
48. Teitelbaum D, Meshorer A, Hirshfeld T, Arnon R, Sela M. Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur J Immunol 1971; 1: 242-248
49. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995; 45: 1268-1276
50. Johnson KP, Due DL. Benefits of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis. Expert Rev Pharmacoecon Outcomes Res 2009; 9: 205-214
51. Vieira PL, Heystek HC, Wormmeester J, Wierenga EA, Kapsenberg ML. Glatiramer acetate (copolymer-1, copaxone) promotes Th2 cell development and increased IL-10 production through modulation of dendritic cells. J Immunol 2003; 170: 4483-4488
52. Weber MS, Hohlfeld R, Zamvil SS. Mechanism of action of glatiramer acetate in treatment of multiple sclerosis. Neurotherapeutics 2007; 4: 647-1453
53. Borel P, Benkhoucha M, Weber MS, Zamvil SS, Santiago-Raber ML, Lalive PH. Glatiramer acetate treatment does not modify the clinical course of (NZB x BXSB)F1 lupus murine model. Int Immunol 2008; 20: 1313-1319
54. Alcaro MC, Papini AM. Contribution of peptides to multiple sclerosis research. Biopolymers 2006; 84: 349-367
55. Monneaux F, Lozano JM, Patarroyo ME, Briand JP, Muller S. T cell recognition and therapeutic effect of a phosphorylated synthetic peptide of the 70K snRNP protein administered in MRL/lpr mice. Eur J Immunol 2003; 33: 287-296
56. Monneaux F, Hoebeke J, Sordet C, Nonn C, Briand JP, Maillère B, et al. Selective modulation of CD4 T cells from lupus patients by a promiscuous, protective peptide analogue. J Immunol 2005; 175: 5839-5847
57. Page N, Schall N, Strub JM, Quinternet M, Chaloin O, Décossas M, et al. The spliceosomal phosphopeptide P140 controls the lupus disease by interacting with the HSC70 protein and via a mechanism mediated by γδ T cells. PloS ONE 2009; 4: e5273.
58. Monneaux F, Parietti V, Briand JP, Muller S. Importance of spliceosomal RNP1 motif for intermolecular T-B cell spreading and tolerance restoration in lupus. Arthritis Res Ther 2007; 9: R111.
59. Muller S, Monneaux F, Schall N, Rashkov RK, Oparanov BA, Wiesel P, et al. Spliceosomal peptide P140 for immunotherapy of systemic lupus erythematosus. Results of an early phase II clinical trial. Arthritis Rheum 2008; 58: 3873-3883
60. Goulvestre C, Chereau C, Nicco C, Mouton L, Weill B, Batteux F. A mimic of p21WAF1/CIP1 ameliorates murine lupus. J Immunol 2005; 175: 6959-6967
61. Atzeni F, Turiel M, Capsoni F, Doria A, Meroni P, Sarzi-Puttini P. Autoimmunity and anti-TNF-α agents. Ann NY Acad Sci 2005; 1051: 559-569
62. Hoentjen F, van Bodegraven AA. Safety of anti-tumor necrosis factor therapy in inflammatory bowel disease. Hoentjen F, van Bodegraven AA. World J Gastroenterol 2009; 15: 2067-2073
63. Zagury D, Burny A, Gallo RC. Toward a new generation of vaccines: the anti-cytokine therapeutic vaccines. Proc Natl Acad Sci U S A. 2001; 98: 8024-8029
64. Zagury D, Le Buanec H, Mathian A, Larcier P, Burnett R, Amoura Z, et al. IFN α kinoid vaccine-induced neutralizing antibodies prevent clinical manifestations in a lupus flare murine model. Proc Natl Acad Sci USA 2009; 106: 5294-5299
65. Le Buanec H, Delavallée L, Bessis N, Paturance S, Bizzini B, Gallo R, et al. TNFα kinoid vaccination-induced neutralizing antibodies to TNFα protects mice from autologous TNFα-driven chronic and acute inflammation. Proc Natl Acad Sci USA 2006; 103: 19442-19447
66. Bertin-Maghit SM, Capini CJ, Bessis N, Chomilier J, Muller S, Rappaport J, et al. Active immunization against murine IL-1β peptides protects against collagen-induced arthritis. Vaccine 2005; 23: 4228-4235
67. Capini CJ, Bertin-Maghit SM, Bessis N, Haumont PM, Bernier EM, Muel EG, et al. Active immunization against murine TNFα peptides in mice: generation of autologous antibodies cross-reacting with the native cytokine and clinical protection. Vaccine 2004; 22: 3144-3153
68. + T cell epitope GP33. J Biol Chem 1999; 274: 5550-5556
69. Fauchère JL, Thurieau C. Evaluation of the stability of peptides and pseudopeptides as a tool in peptide drug design. Adv Drug Res 1992; 23: 127-159
70. Guichard G, Benkirane N, Zeder-Lutz G, Van Regenmortel MHV, Briand JP, Muller S. Antigenic mimicry of natural L-peptides with retro-inverso peptidomimetics. Proc Natl Acad Sci USA 1994; 91: 9765-9769
71. Benkirane N, Guichard G, Van Regenmortel MHV, Briand JP, Muller S. Cross-reactivity of antibodies to retro-inverso peptidomimetics with the parent protein histone H3 and chromatin core particle: specificity and kinetic rate constant measurements. J Biol Chem 1995; 270: 11921-11926
72. Briand JP, Guichard G, Dumortier H, Muller S. Retro-inverso peptidomimetics as new immunological probes: validation and application to the detection of autoantibodies in rheumatic diseases. J Biol Chem 1995; 270: 20686-20691
73. Briand JP, Benkirane N, Guichard G, Newman JFE, Van Regenmortel MHV, Brown F, et al. A retro-inverso peptide corresponding to the GH loop of foot-and-mouth disease virus elicits high levels of long lasting protective neutralizing antibodies. Proc Natl Acad Sci USA 1997; 94: 12545-12550
74. Nargi F, Kramer E, Mezencio J, Zamparo J, Whestone C, Van Regenmortel MHV, et al. Protection of swine from foot-and-mouth disease with one dose of an all-D-retro peptide. Vaccine 1999; 17: 2888-2893
75. Petit MC, Benkirane N, Guichard G, Phan Chan Du A, Marraud M, Cung MT, et al. Solution structure of a retro-inverso peptide analogue mimicking the foot-and-mouth disease virus major antigenic site: Structural basis for its crossreactivity with the parent peptide. J Biol Chem 1999; 274: 3686-3692
76. Phan Chan Du A, Petit MC, Guichard G, Briand JP, Muller S, Cung MT. Structure of antibody-bound peptides and retro-inverso analogues. A transferred nuclear Overhauser effect spectroscopy and molecular dynamics approach. Biochemistry 2001; 40: 5720-5727
77. Ben Yedidia T, Beignon AS, Partidos CD, Muller S, Arnon R. A retro-inverso peptide analogue of influenza virus hemagglutinin Bcell epitope 91-108 induces a strong mucosal and systemic immune response and confers protection in mice after intranasal immunization. Mol Immunol 2002; 39: 323-331
78. Fromme B, Eftekhari P, Van Regenmortel M, Hoebeke J, Katz A, Millar R. A novel retro-inverso gonadotropin-releasing hormone (GnRH) immunogen elicits antibodies that neutralize the activity of native GnRH. Endocrinology 2003; 144: 3262-3269
79. Guichard G, Calbo S, Muller S, Kourilsky P, Briand JP, Abastado JP. Efficient binding of reduced peptide bond pseudopeptides to major histo-compatibility complex class I molecule. J Biol Chem 1995; 270: 26057-26059
80. Benkirane N, Guichard G, Briand JP, Muller S. Exploration of requirements for peptidomimetic immune recognition: antigenic and immunogenic properties of reduced peptide bond pseudopeptide analogues of a histone hexapeptide. J Biol Chem 1996; 271: 33218-33224
81. Phan Chan Du A, Limal D, Semetey V, Dali H, Jolivet M, Desgranges C, et al. Structural and immunological characterization of heteroclitic peptide analogues corresponding to the 600-612 region of the HIV envelope gp41 glycoprotein. J Mol Biol 2002; 323: 503-521
82. Dali H, Busnel O, Hoebeke J, Bi L, Decker P, Briand JP, et al. Heteroclitic properties of mixed α- and aza-β3-peptides mimicking a supradominant CD4 T cell epitope presented by nucleosome. Mol Immunol 2007; 44: 3024-3036
83. Webb AI, Dunstone MA, Williamson NA, Price JD, de Kauwe A, Chen W, et al. T cell determinants incorporating β-amino acid residues are protease resistant and remain immunogenic in vivo. J Immunol 2005; 175: 3810-3818
84. Bartnes K, Hannestad K, Guichard G, Briand JP. A retro-inverso analog mimics the cognate peptide epitope of a CD4+ T cell clone. Eur J Immunol 1997; 27: 1387-1391
85. Mézière C, Viguier M, Dumortier H, Lo-Man R, Leclerc C, Guillet JG, et al. In vivo T helper cell response to retro-inverso peptidomimetics. J Immunol 1997; 159: 3230-3237
86. Ostankowitch M, Guichard G, Connan F, Muller S, Chaboissier A, Hoebeke J, et al. A partially modified retro-inverso pseudopeptide modulates the cytokine profile of cytotoxic T-lymphocytes specific for an influenza virus epitope. J Immunol 1998; 161: 200-208
87. Nair DT, Kaur KJ, Singh K, Mukherjee P, Rajagopal D, George A, et al. Mimicry of native peptide antigens by the corresponding retro-inverso analogs is dependent on their intrinsic structure and interaction propensities. J Immunol 2003; 170: 1362-1373
88. Hin S, Zabel C, Bianco A, Jung G, Walden P. N-hydroxy peptides: a new class of TCR antagonists. J Immunol 1999; 163: 2363-2367
89. Marino M, Ippolito A, Fassina G. Inhibition of experimental autoimmune encephalomyelitis in SJL mice by oral administration of retro-inverso derivative of encephalitogenic epitope P87-99. Eur J Immunol 1999; 29: 2560-2566
90. Katsara M, Matsoukas J, Deraos G, Apostopulos V. Towards immunotherapeutics drugs and vaccines against multiple sclerosis. Curr Med Chem 2006; 13: 2221-2232
91. Ali N, Manolios N. Peptide delivery systems. Lett Pept Sci 2002; 8: 289-294
92. Futaki S. Membrane-permeable arginine-rich peptides and the translocation mechanisms. Adv Drug Deliv Rev 2005; 547-558
93. Partidos CD, Beignon AS, Semetey V, Briand JP, Muller S. The bare skin and the nose as non invasive routes for administering peptide vaccines. Vaccine 2001; 19: 2708-2715
94. Partidos CD, Muller S. Decision making at the surface of the intact or barrier disrupted skin: potential applications for vaccination or therapy. Cell Mol Life Sci 2005; 62: 1418-1424
95. Audie J, Boyd C. The Synergistic Use of Computation, Chemistry and Biology to Discover Novel Peptide-Based Drugs: The Time is Right. Curr Pharm Des 2009 Nov 25.
96. Mouhat S, Andreotti N, Jouirou B, Sabatier JM. Animal toxins acting on voltage-gated potassium channels. Curr Pharm Des 2008; 14(24): 2503-2518
97. Willis CL, Davis TP. Chronic inflammatory pain and the neurovascular unit: a central role for glia in maintaining BBB integrity? Curr Pharm Des 2008; 14(16): 1625-1643